-- Pharmaceutical firm SSY Group (HKG:2005) said it received drug production and registration approvals for three of its products in China, according to a Hong Kong bourse filing Wednesday.
The approval from China's National Medical Products Administration covers a fat-soluble vitamin injection, metformin hydrochloride tablets for type 2 diabetes, and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We adjust our target price to USD19 from USD21, implying 8.2x of our 2026 EPADS, below its three-year historical forward P/E of 12.9x to reflect the long-term growth uncertainty on the back of the still elevated excess mortality rate. FME's Q1 2026 revenue fell 5.5% mainly due to currency headwinds, with organic growth remaining positive at 3.9%, while the operating margin (excluding special items) improved 0.7%-pts. The results were supported by FME25+ savings, the rollout of the 5008X CAREsystem, and the TDAPA reimbursement tailwinds. However, the U.S. same market treatment growth remained challenged, hit by missed treatments. FME reaffirmed its 2026 guidance, with 1H expecting to be stronger before TDAPA benefits phase out in 2H. We adjust our EPADS estimates to EUR1.98 from EUR2.03 for 2026 and to EUR2.16 from EUR2.20 for 2027 to account for the results. While the sustained FME25+ cost savings is positive, the timeline for U.S. same market volume recovery remains uncertain, which we see as a key concern.
WiseTech Global (ASX:WTC) reaffirmed its fiscal 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance of AU$550 million to AU$585 million on a reported basis, providing confidence that it is on the right trajectory to return to an EBITDA margin of over 50% in fiscal 2028, Jefferies said in a note on Tuesday.The firm also offered clarity around its one-off costs, separating restructuring costs of AU$37.5 million as well as mergers and acquisition expenses of AU$11 million to AU$15 million.Amazon is opening its end-to-end logistics capabilities to external enterprise shippers, which could lead to a second-order impact for WiseTech. Traditional freight forwarders and logistics providers, its core customer base, may lose market share to Amazon, but it could also be a catalyst for them to modernize their information technology systems using CargoWise and E2open from WiseTech.The investment firm retained its buy rating and price target of AU$72 on WiseTech.WiseTech Global's shares shed about 2% in recent Wednesday trade.
The Lottery's (ASX:TLC) updated dividend framework should keep leverage within range, although higher NIC drag on cashflow sees limited improvement in dividend yield, Jefferies said in a note on Tuesday.It secured an agreement with the Victorian state government for a 40-year extension of the public lottery license. The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state. The payment will be entirely made in the first half of fiscal year 2027.The analysts expect the firm's focus to be on organic growth opportunities, and it is likely to target additional revenue opportunities, such as portfolio enhancement, going forward.The investment firm retained a hold rating and cut the price target to AU$5.60 per share from AU$6 per share.